PharmiWeb Recruiter Blog

DEERFIELD, Ill. - 2023-07-25

• Partnership combines Roche’s proven track record of successfully developing and launching innovative medicines worldwide with Alnylam’s leadership in RNAi therapeutics
• Zilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressure
• Hypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.¹

Basel, 24 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a new partnership with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic currently in Phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable risk factor for death and disability, with approximately 80% of the adults with hypertension worldwide not being able to effectively manage their blood pressure.¹

– $6 Million USD in Funding Will Help Address Health Disparities Among Indigenous Communities with a Focus on HIV and Viral Hepatitis –

In this article, we’ve put together a list of the best life science organisations to work for in the UK, using the official rankings awarded by The Great Place to Work Institute in 2023.

INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.

Supporting You with UC Provides Patients with Resources to Help Manage Their UC and Tips on Ways to Communicate with Their Doctor

AI is already transforming the recruitment landscape, with 85% of recruiters agreeing that this technology is a useful tool in the hiring process. New developments and use cases for AI are being unleashed at an astonishing rate, and if you aren’t already looking at how you can use this technology to your advantage, now is the time to do so.

• Advances World-Class Clinical Research Capabilities with Leading Regulatory-Grade Registries Platform
• Expected to Be Immediately Accretive to Adjusted Earnings Per Share ¹

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced it has entered into a definitive agreement to acquire CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash.

In today’s competitive job market and taxing economy, finding the right talent for your organisation whilst sticking to tight budgets can be a real challenge – yet it’s not impossible. By implementing cost-effective strategies, you can streamline your hiring procedures, attract qualified candidates, and make efficient use of your resources.

BURLINGTON, N.C., July 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has completed the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial management, patient access and technology solutions to pharmaceutical and biotechnology organizations around the world. Fortrea will begin trading on the NASDAQ Stock Market under the symbol "FTRE" effective at the market opening today.